Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Would be a big help, the volume today was pretty impressive, more would assist the break-out.
Sure is getting some wild fluctuation days.
Never seen anything like that in a V bottle. Looks like a machine mechanical problem.
After covid vaccine:
Should You Avoid Pain Relievers After the COVID-19 Vaccine?
www.healthline.com › health-news › should-you-take-p...
Jan 28, 2021 — Aches and fever are common side effects of coronavirus vaccination. But will taking acetaminophen or ibuprofen affect how well the vaccine ...
Common questions
What pain reliever can I take after Covid vaccine?
Pain relief medications like Tylenol and Advil are 'perfectly fine' – but only after COVID-19 vaccine, experts say. Avoid pain relief medications just before getting the COVID-19 vaccine, but they are 'perfectly fine' to take after, experts say. Headache, fever, body aches and chills.6 days ago
I can't thank all of you guys working on this enough, trying to right all these wrongs. The V users and all of us stockholders owe you, big-time.
Clovis Oncology to Highlight Data at ASCO 2021 Genitourinary Cancers Symposium Virtual Meeting
Thu, February 4, 2021, 5:00 AM
Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that two abstracts featuring data from clinical studies evaluating Rubraca® (rucaparib) in metastatic castration-resistant prostate cancer (mCRPC) and one abstract describing adverse events associated with mCRPC treatment based on real world evidence have been accepted for poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancers Symposium to be held virtually, February 11-13, 2021.
"These data underscore our continued commitment to fully understanding the clinical role of Rubraca and to accelerating the delivery of transformative therapies to the advanced prostate cancer community," said Patrick J. Mahaffy, President and CEO of Clovis Oncology. "The data that will be shared add to growing scientific knowledge about the science of mCRPC and broaden our understanding of Rubraca as a treatment option for patients diagnosed with mCRPC."
The following Clovis-sponsored abstracts will be available on February 8 at 5:00 pm ET and will also be available as posters for viewing starting February 11 at 8:00 am ET on ASCO's Meeting Library. The posters can also be viewed at https://www.clovisoncology.com/pipeline/scientific-presentations/ starting February 11 at 8:00 am ET.
Abstract Number 80: Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC)
Poster Session: Prostate Cancer - Advanced Disease
Date/Time: Thursday, February 11 at 8:00 am ET
Lead Author: Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, New York
Abstract Number 79: Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase 1b RAMP study
Poster Session: Prostate Cancer - Advanced Disease
Date/Time: Thursday, February 11 at 8:00 am ET
Lead Author: Arpit Rao, MBBS, University of Minnesota Medical School, Minneapolis, Minnesota
Abstract Number 61: Clinically significant events associated with metastatic castration-resistant prostate cancer (mCRPC) treatments
Poster Session: Prostate Cancer - Advanced Disease
Date/Time: Thursday, February 11 at 8:00 am ET
Lead Author: Kelvin A. Moses, MD, PhD, FACS, Vanderbilt University Medical Center, Nashville, Tennessee
About Rubraca (rucaparib)
Rubraca is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed multiple tumor types, including ovarian and prostate cancers, as monotherapy and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway. Clovis holds worldwide rights for Rubraca.
Rubraca U.S. FDA Approved mCRPC Indication
Rubraca is indicated for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Rubraca.
This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Select Important Safety Information
Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML) has occurred in patients treated with Rubraca, and are potentially fatal adverse reactions. In 1146 treated patients, MDS/AML occurred in 20 patients (1.7%), including those in long term follow-up. Of these, 8 occurred during treatment or during the 28 day safety follow-up (0.7%). The duration of Rubraca treatment prior to the diagnosis of MDS/AML ranged from 1 month to approximately 53 months. The cases were typical of secondary MDS/cancer therapy-related AML; in all cases, patients had received previous platinum-containing regimens and/or other DNA damaging agents. In TRITON2, MDS/AML was not observed in patients with mCRPC (n=209) regardless of homologous recombination deficiency (HRD) mutation.
Do not start Rubraca until patients have recovered from hematological toxicity caused by previous chemotherapy (≤ Grade 1). Monitor complete blood counts for cytopenia at baseline and monthly thereafter for clinically significant changes during treatment. For prolonged hematological toxicities (> 4 weeks), interrupt Rubraca or reduce dose and monitor blood counts weekly until recovery. If the levels have not recovered to Grade 1 or less after 4 weeks or if MDS/AML is suspected, refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue Rubraca.
Based on findings in genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential or who are pregnant to use effective methods of contraception during treatment and for 3 months following last dose of Rubraca. Advise male patients not to donate sperm during therapy and for 3 months following the last dose of Rubraca.
Most common adverse reactions in TRITON2 (≥ 20%; Grade 1-4) were fatigue/asthenia (62%), nausea (52%), anemia (43%), AST/ALT elevation (33%), decreased appetite (28%), rash (27%), constipation (27%), thrombocytopenia (25%), vomiting (22%), and diarrhea (20%).
Co-administration of rucaparib can increase the systemic exposure of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates, which may increase the risk of toxicities of these drugs. Adjust dosage of CYP1A2, CYP3A, CYP2C9, or CYP2C19 substrates, if clinically indicated. If co-administration with warfarin (a CYP2C9 substrate) cannot be avoided, consider increasing frequency of international normalized ratio (INR) monitoring.
Click here for full Prescribing Information for Rubraca.
You may also report side effects to Clovis Oncology, Inc. at 1-415-409-7220 (US toll) or 1-844-CLVS-ONC (1-844-258-7662; US toll-free).
About Clovis Oncology
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the U.S., Europe and additional international markets. Clovis Oncology targets development programs at specific subsets of cancer populations, and simultaneously develops, with partners, diagnostic tools intended to direct a compound in development to the population that is most likely to benefit from its use. Clovis Oncology is headquartered in Boulder, Colorado, and has additional offices in the U.S. and Europe. Please visit clovisoncology.com for more information.
I think they were giving V to front-line healthcare workers. They should have known the results in lass than a month. Certainly good news would be leaking by now. I expect they are going to try and get in front of leaks and make something official.
I reckon we'll find out pretty soon.
Thanks for posting - I guess this could be huge, if we get any press, out of it.
My spanish not very good. Does this mean we get a preview of early results on Feb 5th?
Those libjudges should be in jail. I sure hope we can right this wrong - before it harms all of the biotech sphere.
Wow, we're over $20K now. I hope $23K is enough to get it done.
And there lies the problem - they are artificial skin, while PTE has the real McCoy, including hair. Good explanation on their web-site.
Ralphey,
Just got their second patent today and there isn't ANY competition. The stock got trashed by some thieving short sellers.
Check the pics on their web-site.
Ah, got it, a second patent.
They got that patent a couple of weeks ago.
Some serious volume there, after it took out the $1.14 seller. Wonder what's going on today.
Wow, what a move, and on huge volume.
Ralphy, that sounds good, I'll check it out.
Would you venture an opinion on PTE - Polarity? I think they have a winner - new skin.
Wow, it was below $4 in Nov - talk about a power move.
Sweet, nice move on volume
and my AMRN starting to run, also
I think this is all about that broad label.. Some big-player tutes read that and figured it out - yurp is going to put our V on the WORLD map.
Hindu, then this is very good news.. I'm sorry, most of this stuff is over my head, I'm an electrician.
Just a guess then - maybe twice as many ppl in yurp can be put on V ??
This is what the EMA said:
The full indication is:
Vazkepa is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL) and established cardiovascular disease, or diabetes, and at least one other cardiovascular risk factor.
===========================================
Isn't this very good news?? Is this what you would call a broad label?
Robinhood is advertising on TV now, just saw an ad - free stock when you sign up. Channel 271 on directv.
Interesting, maybe V will help with this, also:
https://www.medscape.com/viewarticle/945130?src=mkm_covid_update_210202_MSCPEDIT&uac=362266DV&impID=3168936&faf=1
Wow, Z, very well written.
Hmmmmm, pretty good volume in the A H session, and up a good %age. Wonder what's going on now.
Two days in a row, hope I don't jinx the action.
Seems apparent that the PTE board and management are worried about losing control of the company. They have a very valuable process, so I'm not sure I blame them.
This is the highest close since April of last year, quite a feat.
It's definitely trading wildly. Not sure what is causing the wild gyrations. Very likely it's getting ready to make a big move. The next 2 weeks should reveal what's going to happen.
GME - this sounds plausible:
https://stansberryinvestor.com/media-article/90020212
Well done, Captain.
Lizzy, you certainly put up some excellent posts.
Quite a thought, what would happen if the company announced a large order from Argentina/other SA country??
That would likely be the surprise that's needed to blow the shorts out of the water and get the hot-money to switch to the buy side.
I won't be surprised, when it happens.
Styles, thanks for your work on this, I think you nailed it.
Yup, when the SEC did away with the up-tick rule, it changed the mkt into a casino.. Dumbest thing they ever did.
O I on today's $7.50 calls was only 1700, but they still ripped em all off.